Biovest Expanding in Coon Rapids, Minnesota, to Develop Cancer Vaccine
The Coon Rapids Housing and Redevelopment Authority will contribute an additional $100,000 and facility owner JMS Holdings will invest $1.15 million in facility improvements.
"The Minneapolis area is rich with resources vital to a biotechnology company's growth needs, and it is with great appreciation that we thank the state of Minnesota, the city of Coon Rapids, and JMS Holdings for investing in our future," said Biovest President Samuel Duffey.
Biovest will add 14 jobs to its existing work force of 24 employees. It is planning to produce the first cancer vaccine to treat non-Hodgkin's lymphoma. The company has been located in Coon Rapids for nearly 30 years.
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
A Heightened Focus on Reshoring
COVID-19 and Site Selection in the Near and Long Term
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
34th Annual Corporate Survey & the 16th Annual Consultants Survey